Kentaro Kohagura, Sunao Kojima, Kazuaki Uchiyama, Naoto Yokota, Eiichi Tokutake, Yutaka Wakasa, Shinya Hiramitsu, Masako Waki, Hideaki Jinnouchi, Hirokazu Kakuda, Takahiro Hayashi, Naoki Kawai, Masahiro Sugawara, Hisao Mori, Kenichi Tsujita, Kunihiko Matsui, Ichiro Hisatome, Yusuke Ohya, Kazuo Kimura, Yoshihiko Saito, Hisao Ogawa
Effect of urate-lowering on renal outcomes in patients at high-risk for cardiovascular disease with hyperuricemia without gout is not known. We conducted a post hoc analysis of a randomized trial (Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy [FREED]). The FREED trial enrolled 1070 asymptomatic, hyperuricemic elderly patients with at least one risk factor for cardiovascular disease, divided into febuxostat (n = 537) and non-febuxostat (n = 533) groups...
June 2023: Hypertension Research: Official Journal of the Japanese Society of Hypertension